Altimmune to Participate in Two Upcoming Investor Conferences
Altimmune (NASDAQ:ALT), a late clinical-stage biopharmaceutical company focused on liver and cardiometabolic diseases, has announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Altimmune (NASDAQ:ALT), a late clinical-stage biopharmaceutical company focused on liver and cardiometabolic diseases, has announced its participation in two upcoming investor conferences. Management will present at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025, at 10:30 a.m. ET, and the H.C. Wainwright Liver Disease Virtual Conference on October 21, 2025, at 7:00 a.m. ET.
Both presentations will feature fireside chats and will be available via webcast through the Events section of Altimmune's website. The company's management team will also be available for one-on-one meetings with investors during these events.
Details
News Market Reaction – ALT
On Sep 23, the day this news came out, ALT closed 4.29% below the previous close.
Data tracked by StockTitan Argus for the Sep 23 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:
- Stifel 2025 Virtual Cardiometabolic Forum
Tuesday, September 30, 2025
Fireside Chat at 10:30 a.m. Eastern Time
- H.C. Wainwright Liver Disease Virtual Conference
Tuesday, October 21, 2025
Fireside Chat at 7:00 a.m. Eastern Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), Alcohol-associated Liver Disease (ALD) and obesity. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
This press release was published by a CLEAR® Verified individual.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.